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Abstract
Folate deficiency has been associatedwith colorectal cancer risk andmay be involved in colorectal carcinogenesis through
increased chromosome instability, gene mutations, and aberrant DNA methylation. Within the Netherlands Cohort Study
on diet and cancer, we investigated the associations between dietary folate intake and colorectal cancer risk with (APC1)
and without (APC2) truncating APCmutations, accounting for hMLH1 expression and K-rasmutations. In total, 528 cases
and 4200 subcohort members were available for data analyses of the study cohort (n ¼ 120,852) from a follow-up period
between 2.3 and 7.3 y after baseline. Adjusted gender-specific incidence rate ratios (RR) over tertiles of folate intake were
calculated in case-cohort analyses for colon and rectal cancer. Although relatively high folate intake was not associated
with overall colorectal cancer risk, it reduced the risk of APC2colon tumors in men (RR 0.58, 95% CI 0.32–1.05, Ptrend ¼
0.06 for the highest vs. lowest tertile of folate intake). In contrast, it was positively associated with APC1 colon tumors in
men (highest vs. lowest tertile: RR 2.77, 95% CI 1.29–5.95, Ptrend ¼ 0.008) and was even stronger when the lack of
hMLH1 expression and K-ras mutations were excluded (RR 3.99, 95% CI 1.43–11.14, Ptrend ¼ 0.007). Such positive
associations were not observed among women; nor was folate intake associated with rectal cancer when APC mutation
status was taken into account. Relatively high folate consumption reduced the risk of APC2 colon tumors, but folate intake
was positively associated with APC1 colon tumors amongmen. These opposite results may indicate that folate enhances
colorectal carcinogenesis through a distinct APC mutated pathway. J. Nutr. 136: 3015–3021, 2006.
Introduction
Folate deficiency is hypothesized to increase the risk of colorec-
tal carcinogenesis through various mechanisms (1). It can cause
uracil misincorporation in DNA, which in turn may lead to
DNA strand breaks and chromosome instability. In addition, a
low folate status can cause global DNA hypomethylation and
hypermethylation of promoter regions, which may impair the
expression of tumor suppressor genes and DNA repair genes (1).
Considering these mechanisms, it could be expected that suffi-
cient intake of dietary folate protects against colorectal cancer.
Epidemiological studies on the relation between dietary folate
intake and colorectal cancer risk however, have not consistently
shown a protective effect of high folate intake (2,3). This
inconsistency may partly be explained by the possible dual role
of folate in carcinogenesis; that is, folate would prevent carci-
nogenesis in normal healthy tissue but may promote growth of
existing tumors (4). In addition, accounting for molecular events
underlying the carcinogenic process may further clarify the effect
of folate intake on colorectal carcinogenesis, but this was not
addressed in most of these epidemiological studies.
A well-characterized molecular alteration in colorectal car-
cinogenesis is the occurrence of mutations in the adenomatous
polyposis coli (APC)7 gene. Somatic mutations in this tumor sup-
pressor gene were found mainly in its mutation cluster region in
a significant proportion of sporadic colorectal carcinomas, vary-
ing from 34 to.80% (5–8). This underscores the importance of
APC gene mutations in sporadic colorectal carcinogenesis. In an
earlier study in colorectal cancer patients (8) we found that 37%
of the patients had tumors harboring an APC mutation resulting
in a stop codon, which leads to a truncated and therefore inac-
tive APC protein. In addition, Diergaarde et al. (9) found an
indication for a positive association between folate intake and1 Financial support was granted by the Dutch Cancer Society (UM2004-3171 and
UM 99-1980) and The Netherlands Organization for Scientific Research
(980-10-26).
6 Present address: Cancer Research Center of Hawaii, University of Hawaii,
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colorectal adenomas, but the associations did not differ between
adenomas with or without truncating APC mutations. In an-
other study, Diergaarde et al. (10) observed a differential
association between the consumption of green leafy vegetables,
an important source of dietary folate, and the risk of carcinomas
with or without truncating APC mutations.
The exact mechanism through which folate may alter APC
functionality remains unclear, however. Possibly, there is an
indirect effect of decreased activity of the DNA repair gene O6-
methylguanine DNA methyltransferase (O6-MGMT), which
was found to be associated with hypermethylation of its pro-
moter region (11). Consequently, this can lead to an increased
risk of tumors with G:C.A:T mutations in other key genes, like
APC, involved in colorectal cancer (12,13).
Several studies have suggested that colorectal tumors may
arise through distinct pathways based on specific molecular
alterations. In this respect, mutations in APC and Kirsten ras
(K-ras) occur less often in tumors with microsatellite instability
(MSI) compared with microsatellite stable ones (14–17). MSI is
known to be strongly associated with the lack of expression of
the DNA mismatch repair gene human mut-L homologue
1 (hMLH1) (18,19). Tumors harboring this type of instability
occur predominantly in the proximal colon, are often poorly
differentiated, and are more frequently present in women at an
older age (14,20). Furthermore, exogenous factors such as
smoking behavior (21,22) and dietary factors (7,23–25) may be
differentially associated with the risk of cancer development in
MSI and non-MSI tumors. In addition, differential associations
were also observed between folate intake and mutations in K-ras
(26–29). Therefore, it is important to account for potential
aberrations in K-ras and hMLH1 and for differences in tumor
location and sex when assessing the potential effect of dietary
folate on colorectal cancer risk and APC mutations.
In view of these findings, this study aimed to investigate the
associations between folate intake and the risk of colon and
rectal cancer, with and without truncating APC mutations. We
also assessed whether these associations were independent of
K-ras mutations and hMLH1 expression. The study was con-
ducted within the framework of the Netherlands Cohort Study
on diet and cancer (NLCS), of which the study population
consumed relatively low levels of dietary folate (insofar as folic
acid fortification is not allowed in the Netherlands) compared
with some other Western countries.
Subjects and Methods
Study population. The participants in this study were incident colon
and rectal cancer patients and subcohort members from the NLCS,
which has been described in detail elsewhere (30). Briefly, the study was
initiated in 1986 and includes 58,279 men and 62,573 women, aged
55–69 y at baseline, who originated from 204 Dutch municipalities with
computerized population registers. Numbers of subcohort members and
cases are displayed in a flow chart (Fig. 1). At baseline, participants
completed a self-administered food frequency questionnaire that also
contained questions about other risk factors for cancer. The entire cohort
has been monitored for cancer occurrence by annual record linkage to
the Netherlands Cancer Registry (9 cancer registries in The Netherlands)
and to Pathologisch Anatomisch Landelijk Geautomatiseerd Archief
(PALGA), a nationwide network and registry of histopathology and cy-
topathology reports (31). Accumulation of person-time in the cohort was
estimated through biennial vital status follow-up of a subcohort of 5000
men and women who were randomly selected after baseline exposure
measurement. Cases with prevalent cancer other than nonmelanoma
skin cancer were excluded from this subcohort, which left 4774 men and
women eligible for analysis.
The PALGA registry was not yet implemented in some of the
municipalities included in the study in 1986 but reached full coverage by
the end of 1988. Incomplete coverage can introduce selection bias, and
preclinical disease can affect exposure status. For these reasons, we
excluded the 1st 2.3 y of follow-up from the analyses. One hundred and
one subcohort members were either deceased or diagnosed with cancer
other than nonmelanoma skin cancer within this period, leaving 4673
men and women for analysis. From 1989 to 1994, 925 incident cases
were identified with histologically confirmed colorectal cancer of which
815 could also be linked to a PALGA report of the lesion. The PALGA
database was used to identify and locate tumor tissue in Dutch pathology
laboratories. Colorectal cancer was classified according to disease site as
follows: colon, i.e., proximal colon (ICD-O-1 codes 153.0, 153.1, 153.4,
153.5, and 153.6), distal colon (153.2, 153.3, 153.7, 153.8, and 153.9),
rectosigmoid (ICD-O-1 code 154.0), and rectum (ICD-O-1 code 154.1).
Information about age, sex, and family history of colorectal cancer at
baseline was retrieved from the NLCS database.
Tissue samples. Tumor material of the colorectal cancer patients was
collected after approval by the ethical review boards of Maastricht
University, the NCR, and PALGA (32). In addition, all pathology
laboratories in The Netherlands agreed to make relevant tissue samples
available from PALGA upon request. From 815 tissue samples that were
scattered over 54 pathology laboratories in the Netherlands, 734 sam-
ples (90%) could be traced and were retrieved between August 1999 and
December 2001.
Gene mutation analyses. Genomic DNA was isolated from the
paraffin sections after macrodissection of tumor cells as previously
described (32). Gene mutation analyses of the mutation cluster region in
Figure 1 Flow diagram of subjects on whom the analyses were based
1 Netherlands Cancer Registry.
2 Pathologisch Anatomisch Landelijk Geautomatiseerd Archief.
3 Patients with rectosigmoid tumors were not included in the analyses.
4 Adenomatous polyposis coli.
5 Mutation cluster region.
6 Kirsten ras.
7 human mut-L homologue 1.
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APC (codons 1286–1520), was performed as previously described (8).
Briefly, nested PCR was used to amplify the mutation cluster region in
4 overlapping DNA fragments, and the purified fragments were
sequenced. Two observers independently evaluated the sequence pat-
terns and data entry. For 72 colorectal cancer patients, one or more
fragments of the APC gene could not be analyzed completely, leaving
662 patients for data analysis.
The exon 1 fragment of the K-ras oncogene, spanning codons 8–29,
was analyzed successfully for all 734 patients using nested PCR,
followed by direct sequencing of purified fragments as described (32).
hMLH1 expression analysis. Immunohistochemical analyses were
performed and scored on 4-mm sections of formalin-fixed, paraffin-
embedded cancer tissue and adjacent normal tissue using a monoclonal
antibody against hMLH1, as previously described (7). Two investigators
reviewed the immunohistochemical staining profiles independently and
discrepancies were reexamined and discussed with a pathologist until
consensus was reached. hMLH1 expression status was determined
successfully in 721 (98%) of 734 patients.
Food frequency questionnaire. The self-administered questionnaire
was a 150-item semiquantitative food frequency questionnaire, which
concentrated on habitual consumption of food and beverages during the
year preceding the start of the study and also contained questions about
body weight and length, smoking status, physical activity, and family
history of colorectal cancer. Daily mean nutrient intakes were calculated
as the cumulated product of the frequencies and portion sizes of all food
items and their tabulated nutrient contents from the Dutch Food
Composition Table (NEVO table, 1986) (33). The questionnaire was
validated through comparison with a 9-d diet record (34). Questionnaire
data were key-entered twice for all incident cases in the cohort and for all
subcohort members in a blinded manner with respect to case or subcohort
status. This was done to minimize observer bias in coding and inter-
pretation of the data.
Folate data were derived from a validated liquid chromatography
trienzyme method (35) used to analyze the 125 most important Dutch
foods contributing to folate intake (36). Mean daily intakes of all other
relevant nutrients were calculated using the computerized Dutch Food
Composition Table (33). Dietary supplement data were also obtained via
the food frequency questionnaire. However, the use of B-vitamins and/or
multivitamin supplements was low (7 and 4%, respectively), and folic
acid was generally not included in supplements in The Netherlands in the
late 1980s. Therefore, folic acid supplement use probably plays a very
minor role in our study population, and dietary supplement use was not
further accounted for in the analyses. Cases and subcohort members with
incomplete or inconsistent dietary data were excluded from analyses
(27,34). Hence, 446 colon cancer cases, 160 rectal cancer cases, 76
rectosigmoid cancer cases, and 4343 subcohort members remained.
Statistical analyses. Data analyses were conducted overall, as well as
stratified for men and women, and for colon and rectal tumors with and
without truncating APC mutations, described here as APC1 tumors and
APC2 tumors, respectively. The group of cases without truncating APC
mutations consisted of cases with tumors containing a wild-type APC
gene (28%), a missense mutation (29%), or a silent mutation (6%).
Because the number of patients with a rectosigmoid tumor was too small
for adequate stratified analyses, we included these patients only when
assessing associations for all colorectal tumors combined. Furthermore,
the rectosigmoid is regarded as a clinically applied term rather than
an anatomically defined transitional zone between the colon and rec-
tum (32).
The analyses were repeated for tumors with APC mutations,
excluding those tumors that also contained activating K-ras mutations
and were hMLH1 deficient. Of 125 truncating APC colon tumors, 64
(49%) exclusively contained a truncating APC mutation. To investigate
the effect of folate on specific point mutations, analyses were conducted
for tumors with G:C . A:T mutations in APC irrespective of the
presence of truncating APC mutations or other gene defects.
The intake of dietary folate and other baseline characteristics were
evaluated for subcohort members and colon and rectal cancer cases, with
or without APC mutations, by calculating the mean and SD of the
continuous variables, which included folate intake (mg/d), age (y), BMI
(kg/m2), energy (kJ/d), alcohol (g/d), total fat (g/d), fiber (g/d), vitamin C
(mg/d), riboflavin (mg/d), vitamin B-6 (mg/d), iron (mg/d) and methi-
onine (mg/d). Distributions of the variables for family history of colo-
rectal cancer (yes/no), smoking status (never/ex/current smoker), and
physical activity during leisure time (,30, 30–60, 60–90, .90 min/d)
were also calculated. Differences in mean values or distributions of var-
iables between groups of cases with and without truncating APC mu-
tations were tested with the Student’s t test, the Mann-Whitney U test, or
the chi-square test where appropriate.
Cox proportional hazards regression models were used to estimate
age-adjusted and multivariate-adjusted gender-specific incidence rate
ratios (RR) and corresponding 95% CI of colon and rectal cancer for
tertiles of folate intake. In addition, associations were estimated for tu-
mors with or without truncating APC mutations. Standard errors of the
RRs were estimated using the robust Huber-White sandwich estimator
to account for additional variance introduced by sampling from the cohort
(37). The proportional hazards assumption was tested using the scaled
Schoenfeld residuals (38). Tests for dose response trends over the different
tertiles of folate intake were estimated by fitting the ordinal exposure
variables as continuous variables and evaluated using the Wald test.
The covariates included in the multivariate analyses were those found
to significantly contribute to the multivariate model (P# 0.05) for colon
and/or rectal cancer, or to influence the RR by.10%. This applied to the
variables for age, family history of colorectal cancer, BMI, energy, fiber,
vitamin C, riboflavin, vitamin B-6, iron and methionine. After excluding
subjects with missing information on $1 of these covariates, 4200
subcohort members remained for statistical analyses, as well as 399
colon and 129 rectal cancer cases with complete APC and K-ras muta-
tion analyses, and 394 colon and 128 rectal cancer cases with additional
complete hMLH1 expression analyses.
Several factors were previously found to be associated with colorec-
tal cancer risk or to be capable of modifying the association between
dietary folate and colorectal cancer risk, i.e., smoking (22,39,40), alco-
hol (41,42), riboflavin, B-6 (43,44), and iron intake (45). We therefore
determined possible effect modification of these factors, as well as for
sex, by testing for interaction and by stratified analyses.
All statistical analyses were performed with the STATA statistical
software package (Intercooled STATA, version 9.1).
Results
We explored mean dietary intakes and other characteristics
measured at baseline for cancer cases and subcohort members.
Folate intake among males with APC1 colon tumors was higher
compared with males with APC2 colon tumors (Table 1). Fur-
thermore, we observed that intakes of riboflavin and iron were
significantly higher among men with APC1 colon tumors com-
pared with men with APC2 colon tumors. All other character-
istics presented in Table 1 did not differ substantially between
tumors with and without truncating APC mutations.
To further investigate the associations among folate intake,
colon cancer risk, and APC mutation status, we calculated rela-
tive risks for men and women (Table 2). Folate intake was not
associated with overall colon cancer risk in either men or
women. However, it reduced the risk of APC2 colon tumors in
men (RR 0.58, CI 0.32–1.05 for the highest vs. the lowest tertile
of folate intake; Ptrend ¼ 0.06). In contrast, there was a strong
positive association between dietary folate and APC1 colon
tumors in men (RR 2.77, CI 1.29–5.95, Ptrend¼ 0.008), whereas
no association could be observed in women with this type of
colon tumor. When calculating associations between folate in-
take and cancer risk for APC1 colon tumors without an addi-
tional mutated K-ras gene and with hMLH1 expression, the
positive association appeared even stronger in men (RR 3.99, CI
1.43–11.14, Ptrend¼ 0.007) but not in women. High folate intake
Folate and APC mutations in colorectal cancer 3017
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tended to reduce the risk of colon tumors in women harboring
G:C. A:T point mutations in the APC gene (RR 0.45, CI 0.18–
1.14; Ptrend ¼ 0.10). This was not observed in men.
Relative risks were also calculated for tumor sublocalizations
within the colon. However, it appeared that folate intake was
neither associated with proximal and distal colon cancer risk,
nor did these relative risks substantially differ from overall colon
cancer risk. Accounting for APC mutations in these subgroups
did not reveal differential results (data not shown).
Regarding rectal cancer, we observed that intake of dietary
folate was neither associated with overall cancer risk nor with
rectal cancer, with or without APC truncating mutations, in
either men or women (see Table 3). However, when conducting
the analyses for APC1 tumors without a K-ras mutation and
with hMHL1 expression, folate tended to be positively associ-
ated with rectal cancer risk among men (RR 3.69, CI 0.97–
13.98; Ptrend ¼ 0.06).
In addition, we assessed possible associations for all colo-
rectal cancer cases combined for each of the endpoints consid-
ered in this study. Folate intake was also positively associated
with APC1 colorectal tumors without a K-ras mutation and
with hMHL1 expression (RR 1.86, CI 0.97–3.55), again, most
pronounced among men (RR 3.40, CI 1.54–7.50), although the
interaction with sex was not significant. Significant interactions
were observed between folate intake and sex in the associations
with overall colon cancer risk (P ¼ 0.03), and APC1 colon
tumors (P ¼ 0.01). None of the other interactions tested were
significant, nor did the remaining stratified analyses reveal any
different relative risks compared with the overall groups.
Discussion
In this study, we investigated the associations between folate
intake and colorectal carcinoma risk with and without truncat-
ing APC mutations. We observed that folate intake in the 2nd
and highest tertile reduced the risk ofAPC2colon tumors among
men, whereas folate intake was positively associated with APC1
colon tumors in men. This positive association among men was
even stronger for APC1 colon tumors, and appeared in rectal
tumors, when tumors with additional aberrations in K-ras and
with hMLH1 expression were excluded.
To our knowledge, the relation between folate and APC
mutations was investigated only once before in colorectal ade-
nomas by Diergaarde et al. (9), but, in contrast to our study, no
differences were observed between the APC2 and APC1 end-
points. Reasons for this discrepancy might be that adenomas
were studied instead of carcinomas, and that a case-control de-
sign was used with selected cases vs. a case-cohort design with inci-
dent cases in our study. Furthermore, in the study of Diergaarde
et al. (9), the analyses were not stratified for gender, which may
have attenuated potential associations in men. On the other
TABLE 1 Baseline dietary intake and other characteristics of cancer cases and subcohort members from the Netherlands Cohort
Study on diet and cancer in 19861
Men Women
Colon Rectum Colon Rectum
Characteristic Subcohort APC2 2 APC1 3 APC2 APC1 Subcohort APC2 APC1 APC2 APC1
n 2040 143 70 46 38 2136 131 55 26 19
Folate, mg/d 224.9 6 75.2 215.8 6 65.6 247.9 6 67.9* 221.6 6 52.1 218.1 6 69.8 198.7 6 67.2 186.7 6 69.2 195.2 6 56.9 218.5 6 94.8 211.0 6 56.9
Age, y 61.3 6 4.2 63.0 6 4.3 62.7 6 3.9 62.2 6 4.7 62.4 6 3.6 61.4 6 4.3 63.3 6 3.9 62.7 6 4.2 62.2 6 4.0 62.9 6 3.3
Family history, % yes 5.4 11.9 8.6 6.5 15.8 5.7 9.9 12.7 15.4 0
BMI, kg/m2 25.0 6 2.6 25.5 6 2.9 25.7 6 2.9 25.2 6 2.6 24.8 6 2.7 25.1 6 3.56 25.4 6 3.7 25.9 6 3.2 25.4 6 3.9 25.7 6 3.0
Smoking status, %
Never 12.8 11.9 8.6 8.7 13.2 58.2 61.8 74.6 57.7 73.7
Exsmoker 51.7 65.7 64.3 56.5 52.6 20.6 24.4 16.4 30.8 10.5
Current smoker 35.5 22.4 27.1 34.8 34.2 21.2 13.7 9.1 11.5 15.8
Physical activity,4 %
,30 min/d 17.7 9.9 20.3 13.3 15.8 24.3 28.7 33.3 23.1 47.4
30–60 min/d 30.5 35.5 30.4 20.0 36.8 31.3 31.0 27.8 42.3 21.1
60–90 min/d 18.8 22.0 14.5 22.2 13.2 22.7 21.7 20.4 23.1 26.3
.90 min/d 32.0 32.6 34.8 44.4 34.2 21.7 18.6 18.5 11.5 5.3
Dietary factors
Energy, kJ/d 9084 6 2134 8815 6 1698 9183 6 2166 9204 6 1769 8875 6 1604 7044 6 1656 6785 6 1492 7239 6 2003 7071 6 1415 7592 6 1296
Alcohol,5 g/d 14.9 6 16.8 15.3 6 15.9 16.8 6 18.8 15.2 6 17.1 18.6 6 19.4 5.8 6 9.5 6.2 6 12.2 3.9 6 9.2 6.8 6 7.9 5.8 6 11.2
Fat, g/d 94.3 6 28.4 92.0 6 23.5 94.1 6 28.8 93.0 6 24.5 89.7 6 25.4 73.9 6 22.7 71.5 6 21.9 77.1 6 25.8 74.3 6 22.2 83.5 6 18.8
Fiber, g/d 28.7 6 8.7 28.9 6 7.7 30.3 6 7.9 30.0 6 7.7 29.1 6 10.2 25.3 6 7.0 24.2 6 7.5 24.8 6 7.2 24.6 6 4.0 26.3 6 5.3
Vitamin C, mg/d 98.8 6 42.9 102.3 6 42.9 111.6 6 42.9 113.9 6 51.9 98.7 6 48.0 108.6 6 44.5 101.9 6 48.8 105.6 6 43.1 114.8 6 34.0 117.5 6 52.2
Riboflavin, mg/d 1.58 6 0.45 1.53 6 0.39 1.65 6 0.44* 1.53 6 0.35 1.49 6 0.34 1.45 6 0.41 1.37 6 0.34 1.46 6 0.44 1.53 6 0.48 1.53 6 0.29
Vitamin B-6, mg/d 1.54 6 0.38 1.54 6 0.35 1.62 6 0.37 1.58 6 0.35 1.46 6 0.40 1.33 6 0.32 1.28 6 0.30 1.37 6 0.37 1.34 6 0.27 1.45 6 0.32
Iron, mg/d 13.2 6 3.3 13.3 6 3.0 14.5 6 2.8* 13.6 6 2.6 13.5 6 3.3 11.7 6 2.7 11.3 6 2.4 11.3 6 2.5 11.5 6 2.1 12.1 6 2.1
Methionine, mg/d 1716 6 417 1694 6 366 1736 6 387 1658 6 298 1598 6 408 1492 6 366 1442 6 304 1537 6 447 1140 6 337 1613 6 290
1 Values are means 6 SD or %, *Different from APC2, P , 0.05.
2 Tumors without a truncating APC mutation.
3 Tumors with a truncating APC mutation.
4 Information on physical activity was not available for 43 subcohort members, for 6 colon cancer cases, and for 1 rectal cancer case.
5 Information on alcohol intake was not available for 117 subcohort members, for 4 colon cancer cases, and for 4 rectal cancer cases.
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hand, the ranges of dietary folate intake within the tertiles of
intake were comparable to those in our study population. In
another study by Diergaarde et al. (10), intake of green leafy
vegetables, an important source of dietary folate, was inversely
associated withAPC2colon carcinomas. Although the association
with folate intake was not calculated separately in that study, the
results suggest a similarity with the inverse association between
folate and APC2 colon carcinomas in our study. However, the
reason why the protective influence of folate is confined to these
tumors remains unclear and needs further investigation.
After determining potential interactions, we found that sex
significantly modified the effect of folate intake on overall colon
cancer risk, as well as on APC1 colon tumors. For this reason,
we presented the data for men and women separately despite the
drawbacks of thereby creating smaller subgroups and less-precise
estimations. To minimize the potential danger of reporting chance
findings, however, we also conducted analyses for all colorectal
tumors combined, with and without stratifying for sex. We then
observed that folate intake was again positively associated with
APC1 colorectal tumors without a K-ras mutation and with
hMHL1 expression, and that this effect was only present among
men.
Although one could argue that the number of cases in some
subgroups should preferably have been higher, we emphasize
that the selection of patients in this study was based on the
availability of tissue samples with sufficient extracted DNA as
well as the completeness of analyses of the K-ras and APC genes
and hMLH1 expression. This led to a reduction of the number of
cases that could be included in the analyses. However, a tissue
sample, as well as a sufficient amount of DNA, was available
for 90% of the patients. Moreover, the overlap of available
molecular analyses was high (89%). Finally, it is important to
realize that the characteristics of these patients with regard to
age, sex, family history of colorectal cancer, smoking behavior,
and dietary factors differed neither from the 815 patients ini-
tially identified nor from the 734 patients with sufficient tumor
DNA. It is therefore unlikely that bias occurred due to the se-
lection of patients.
TABLE 3 RR and 95% CI for rectal cancer patients according
to tertiles of folate intake
Men Women
Tertiles of folate intake1 N2 RR3 95% CI N2 RR3 95% CI
Rectal carcinoma, all tumors
1 26 1.00 10 1.00
2 32 1.11 0.63–1.97 18 1.71 0.72–4.04
3 26 0.91 0.41–2.01 17 1.54 0.55–4.33
P-value for linear trend 0.82 0.42
Rectal carcinoma,4 APC2
1 12 1.00 6 1.00
2 19 1.31 0.62–2.77 10 1.78 0.58–5.49
3 15 0.93 0.31–2.72 10 1.80 0.46–6.98
P-value for linear trend 0.89 0.39
Rectal carcinoma,5 APC1
1 14 1.00 4 1.00
2 13 0.95 0.39–2.31 8 1.60 0.41–6.29
3 11 0.92 0.29–2.99 7 1.25 0.25–6.34
P-value for linear trend 0.89 0.82
Rectal carcinoma,6 APC1,
K-ras2, hMLH11
1 5 1.00 1 1.00
2 7 1.98 0.63–6.21 4 3.42 0.30–38.89
3 9 3.69 0.97–13.98 3 2.56 0.16–41.13
P-value for linear trend 0.06 0.52
Rectal carcinoma, G:C . A:T
point mutations in APC
1 12 1.00 7 1.00
2 18 1.34 0.61–2.95 8 1.25 0.37–4.22
3 16 1.15 0.39–3.35 9 1.62 0.39–6.64
P-value for linear trend 0.80 0.50
1 Median intakes of folate within tertiles of folate are 162.7, 211.4, and 279.9 mg/d for
men, and 142.5, 186.8, and 248.0 mg/d for women.
2 Number of person years among subcohort members for the 1st, 2nd, and 3rd tertile
of folate intake is 3243, 3282 and 3293 for men, and 3457, 3512 and 3526 for women,
respectively.
3 RR adjusted for age, family history, BMI, iron, fiber, energy, riboflavin, vitamin B-6,
vitamin C and methionine.
4 Rectal tumors without a truncating APC mutation.
5 Rectal tumors with a truncating APC mutation.
6 Rectal tumors with a truncating APC mutation, no K-ras mutation, and with hMLH1
expression.
TABLE 2 RR and 95% CI for colon cancer patients according
to tertiles of folate intake
Men Women
Tertiles of folate intake1 N2 RR3 95% CI N2 RR3 95% CI
Colon carcinoma, all tumors
1 74 1.00 74 1.00
2 56 0.69 0.46–1.02 64 0.94 0.61–1.44
3 83 0.96 0.61–1.54 48 0.82 0.45–1.49
P-value for linear trend 0.84 0.53
Colon carcinoma,4 APC2
1 60 1.00 56 1.00
2 39 0.56 0.35–0.88 42 0.85 0.52–1.39
3 44 0.58 0.32–1.05 33 0.79 0.40–1.54
P-value for linear trend 0.06 0.47
Colon carcinoma,5 APC1
1 14 1.00 18 1.00
2 17 1.20 0.56–2.55 22 1.21 0.54–2.70
3 39 2.77 1.29–5.95 15 0.91 0.27–3.06
P-value for linear trend 0.008 0.91
Colon carcinoma,6 APC1,
K-ras2, hMLH11
1 7 1.00 11 1.00
2 10 1.58 0.57–4.35 7 0.67 0.18–2.48
3 22 3.99 1.43–11.14 7 0.77 0.13–4.57
P-value for linear trend 0.007 0.75
Colon carcinoma, G:C . A:T
point mutations in APC
1 40 1.00 39 1.00
2 32 0.66 0.39–1.12 34 0.78 0.41–1.49
3 48 0.86 0.46–1.61 20 0.45 0.18–1.14
P-value for linear trend 0.63 0.10
1 Median intakes of folate within tertiles of folate are 162.7, 211.4, and 279.9 mg/d for
men and 142.5, 186.8, and 248.0 mg/d for women.
2 Number of person years among subcohort members for the 1st, 2nd, and 3rd tertile
of folate intake is 3243, 3282, and 3293 for men and 3457, 3512, and 3526 for women.
3 RR adjusted for age, family history, BMI, iron, fiber, energy, riboflavin, vitamin B-6,
vitamin C, and methionine.
4 Colon tumors without a truncating APC mutation.
5 Colon tumors with a truncating APC mutation.
6 Colon tumors with a truncating APC mutation, no K-ras mutation, and with hMLH1
expression.
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High folate intake resulted in an increased risk of APC1
colon tumors among men. However, this was not expected,
given the hypothesis that folate prevents DNA damage. Because
it is reasonable to assume that aberrations in other key genes in
colorectal carcinogenesis may also be associated with folate in-
take, we included K-ras mutation status and hMLH1 expression
in our analyses to exclude their potential underlying influence.
The observations that APC and K-ras mutations may be in-
versely associated with MSI (14–17) and with hMLH1 expres-
sion (18,19) are important reasons to do so. APC mutated colon
tumors, without additional K-ras mutation and with hMLH1
expression, were even more positively associated with folate in-
take in men, and the positive association also appeared for this
type of rectal tumor among men. Interestingly, folic acid supple-
mentation might have a cancer-promoting effect in people with
already-existing, undiagnosed premalignant or malignant le-
sions (4,46). APC mutations play an important role in both
tumor initiation as well as in later stages of colorectal cancer de-
velopment (47). The development of lesions containing early
APC mutations is possibly more sensitive to a high folate intake;
that is, the protective influence of dietary folate on cancer pro-
gression might be decreased after anAPCmutation has occurred
compared with tumors that were initiated otherwise.
Other recent studies confirm that multiple alternative genetic
pathways to colorectal cancer may exist, because it was found
that only a small number of colorectal tumors (5– 6%) harbored
mutations in all 3 key genes K-ras, APC, and TP53 (48,49). We
observed strong positive associations for tumors containing
exclusively APC mutations in men only. This may indicate that
folate potentially mediates an APC mutated pathway in the
colon and rectum in men, but that its effect differs between men
and women. However, the reasons for these differences are
unknown, and clearly, other studies are warranted to confirm or
reject this.
The relative risks of tumors harboring G:C . A:T point
mutations in APC were slightly decreased among women with
colon tumors. Decreased activity of the DNA repair gene O6-
MGMT by epigenetic hypermethylation might be an indirect
mechanism through which folate intake modifies colorectal
cancer risk (11). The O6-MGMT protein removes adducts from
the O6 position of guanine in DNA (12), which in turn prevents
G:C . A:T point mutations. Previously, we reported that O6-
MGMT promoter hypermethylation may partly be due to a low
folate status (50). It has also been reported that that O6-MGMT
hypermethylation is associated with G:C . A:T mutations in
K-ras and TP53 (12,13,27). However, others did not observe an
association between O6-MGMT expression and G:C. A:T mu-
tations in the APC gene alone (51). Further research is therefore
needed to investigate whether APC mutations might occur via
decreased O6-MGMT functionality.
A potential protective effect of folate intake on colorectal
cancer risk has been demonstrated only in 10 of 23 epidemio-
logical studies investigating this association (2). In addition, we
observed higher risks of colorectal cancer in some subgroups
even though intakes of dietary folate in our study population
were relatively low compared with some other Western coun-
tries. This raises the question as to whether high folate intake
should be a reason for concern in terms of colorectal cancer risk,
particularly in view of differences in recommended dietary
intakes between countries and the mandatory fortification of
cereals with folic acid in the United States and Canada. It is
therefore of crucial importance to gain more insight into the role
that dietary folate plays in colorectal carcinogenesis with genetic
aberrations like truncating APC mutations in future studies.
In conclusion, the results of this study indicate that an inverse
association between relatively high folate consumption and
carcinogenesis is limited to APC2 colon tumors, especially in
men. Combined with the higher relative risks ofAPC1 colon and
rectal tumors without additional aberrations in 2 other key
genes involved in colorectal cancer in men, these findings may
indicate that folate intake exerts an effect on specific genetic
pathways, i.e., an APC mutated pathway. Tumors that arise
through distinct genetic pathways on the basis of specific genetic
aberrations, such as truncating APC mutations, possibly have a
unique etiology, and folate may have a different effect on these
pathways in men and women.
Acknowledgments
We thank Dr. M. Brink for the collection of tissue samples;
Dr. M. Brink, Dr. M. Lu¨chtenborg, P. Wark, G. Roemen, and
K. Wouters for molecular analyses; Dr. L. Schouten, S. van de
Crommert, H. Brants, J. Nelissen, C. de Zwart, M. Moll, W.
van Dijk, M. Jansen, and A. Pisters for data management; and
H. van Montfort, T. van Moergastel, L. van den Bosch, and
R. Schmeitz for programming assistance. Finally, we would like
to thank Dr. A. Volovics and Dr. A. Kester for statistical advice.
Literature Cited
1. Kim YI. Folate and DNA methylation: a mechanistic link between folate
deficiency and colorectal cancer? Cancer Epidemiol Biomarkers Prev.
2004;13:511–9.
2. Bollheimer LC, Buettner R, Kullmann A, Kullmann F. Folate and its
preventive potential in colorectal carcinogenesis. How strong is the bi-
ological and epidemiological evidence? Crit Rev Oncol Hematol. 2005;
55:13–36.
3. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ. Folate intake
and colorectal cancer risk: a meta-analytical approach. Int J Cancer.
2005;113:825–8.
4. Ulrich CM, Potter JD. Folate supplementation: too much of a good
thing? Cancer Epidemiol Biomarkers Prev. 2006;15:189–93.
5. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T,
Miki Y, Mori T, et al. Somatic mutations of the APC gene in colorectal
tumors: mutation cluster region in the APC gene. Hum Mol Genet.
1992;1:229–33.
6. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR,
Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early
during colorectal tumorigenesis. Nature. 1992;359:235–7.
7. Diergaarde B, Braam H, van Muijen GN, Ligtenberg MJ, Kok FJ,
Kampman E. Dietary factors and microsatellite instability in spo-
radic colon carcinomas. Cancer Epidemiol Biomarkers Prev. 2003;12:
1130–6.
8. Luchtenborg M, Weijenberg MP, Roemen GM, de Bruine AP, van den
Brandt PA, Lentjes MH, Brink M, van Engeland M, Goldbohm RA,
et al. APC mutations in sporadic colorectal carcinomas from the
Netherlands cohort study. Carcinogenesis. 2004;25:1219–26.
9. Diergaarde B, Tiemersma EW, Braam H, van Muijen GN, Nagengast FM,
Kok FJ, Kampman E. Dietary factors and truncating APC mutations in
sporadic colorectal adenomas. Int J Cancer. 2005;113:126–32.
10. Diergaarde B, van Geloof WL, van Muijen GN, Kok FJ, Kampman E.
Dietary factors and the occurrence of truncating APC mutations in
sporadic colon carcinomas: a Dutch population-based study. Carcino-
genesis. 2003;24:283–90.
11. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactiva-
tion of the DNA repair gene O6-methylguanine-DNA methyltransferase
by promoter hypermethylation is a common event in primary human
neoplasia. Cancer Res. 1999;59:793–7.
12. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA,
Watkins DN, Issa JP, Sidransky D, Baylin SB, et al. Inactivation of the
DNA repair gene O6-methylguanine-DNA methyltransferase by pro-
moter hypermethylation is associated with G to A mutations in K-ras in
colorectal tumorigenesis. Cancer Res. 2000;60:2368–71.
3020 de Vogel et al.
 at Universiteit M
aastricht UB Randwijck - Verwerking on December 19, 2008 
jn.nutrition.org
D
ow
nloaded from
 
13. Esteller M, Risques RA, Toyota M, Capella G, Moreno V, Peinado
MA, Baylin SB, Herman JG. Promoter hypermethylation of the
DNA repair gene O(6)-methylguanine-DNA methyltransferase is
associated with the presence of G:C to A:T transition mutations in
p53 in human colorectal tumorigenesis. Cancer Res. 2001;61:
4689–92.
14. Luchtenborg M, Weijenberg MP, Wark PA, Saritas AM, Roemen GM,
van Muijen GN, de Bruine AP, van den Brandt PA, de Goeij AF.
Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1
in sporadic colorectal carcinomas from the Netherlands Cohort Study.
BMC Cancer. 2005;5:160.
15. Olschwang S, Hamelin R, Laurent-Puig P, Thuille B, De Rycke Y,
Li YJ, Muzeau F, Girodet J, Salmon RJ, et al. Alternative genetic
pathways in colorectal carcinogenesis. Proc Natl Acad Sci USA.
1997;94:12122–7.
16. Salahshor S, Kressner U, Pahlman L, Glimelius B, Lindmark G,
Lindblom A. Colorectal cancer with and without microsatellite insta-
bility involves different genes. Genes Chromosomes Cancer. 1999;
26:247–52.
17. Samowitz WS, Holden JA, Curtin K, Edwards SL, Walker AR, Lin HA,
Robertson MA, Nichols MF, Gruenthal KM, et al. Inverse relationship
between microsatellite instability and K-ras and p53 gene alterations in
colon cancer. Am J Pathol. 2001;158:1517–24.
18. Rajagopalan H, Lengauer C. CIN-ful cancers. Cancer Chemother
Pharmacol. 2004;54:S65–8.
19. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A,
Peltomaki P. Genetic and epigenetic modification of MLH1 accounts
for a major share of microsatellite-unstable colorectal cancers. Am J
Pathol. 2000;156:1773–9.
20. Breivik J, Lothe RA, Meling GI, Rognum TO, Borresen-Dale AL,
Gaudernack G. Different genetic pathways to proximal and distal
colorectal cancer influenced by sex-related factors. Int J Cancer.
1997;74:664–9.
21. Slattery ML, Curtin K, Anderson K, Ma KN, Ballard L, Edwards S,
Schaffer D, Potter J, Leppert M, et al. Associations between cigarette
smoking, lifestyle factors, and microsatellite instability in colon tumors.
J Natl Cancer Inst. 2000;92:1831–6.
22. Luchtenborg M, Weijenberg MP, Kampman E, van Muijen GN,
Roemen GM, Zeegers MP, Goldbohm RA, van ’t Veer P, de Goeij AF,
et al. Cigarette smoking and colorectal cancer: APC mutations, hMLH1
expression, and GSTM1 and GSTT1 polymorphisms. Am J Epidemiol.
2005;161:806–15.
23. Slattery ML, Anderson K, Curtin K, Ma KN, Schaffer D, Samowitz W.
Dietary intake and microsatellite instability in colon tumors. Int J
Cancer. 2001;93:601–7.
24. Wark PA, Weijenberg MP, van ’t Veer P, van Wijhe G, Luchtenborg M,
van Muijen GN, de Goeij AF, Goldbohm RA, van den Brandt PA. Fruits,
vegetables, and hMLH1 protein-deficient and -proficient colon cancer:
the Netherlands cohort study. Cancer Epidemiol Biomarkers Prev.
2005;14:1619–25.
25. Luchtenborg M, Weijenberg MP, de Goeij AF, Wark PA, Brink M,
Roemen GM, Lentjes MH, de Bruine AP, Goldbohm RA, et al. Meat
and fish consumption, APC gene mutations and hMLH1 expression in
colon and rectal cancer: a prospective cohort study (The Netherlands).
Cancer Causes Control. 2005;16:1041–54.
26. Bautista D, Obrador A, Moreno V, Cabeza E, Canet R, Benito E, Bosch
X, Costa J. Ki-ras mutation modifies the protective effect of dietary
monounsaturated fat and calcium on sporadic colorectal cancer. Cancer
Epidemiol Biomarkers Prev. 1997;6:57–61.
27. Brink M, Weijenberg MP, de Goeij AF, Roemen GM, Lentjes MH, de
Bruine AP, van Engeland M, Goldbohm RA, van den Brandt PA.
Dietary folate intake and k-ras mutations in sporadic colon and rectal
cancer in the Netherlands Cohort Study. Int J Cancer. 2005;114:
824–30.
28. Martinez ME, Maltzman T, Marshall JR, Einspahr J, Reid ME,
Sampliner R, Ahnen DJ, Hamilton SR, Alberts DS. Risk factors for
Ki-ras protooncogene mutation in sporadic colorectal adenomas.
Cancer Res. 1999;59:5181–5.
29. Slattery ML, Curtin K, Anderson K, Ma KN, Edwards S, Leppert M,
Potter J, Schaffer D, Samowitz WS. Associations between dietary intake
and Ki-ras mutations in colon tumors: a population-based study. Cancer
Res. 2000;60:6935–41.
30. van den Brandt PA, Goldbohm RA, van ’t Veer P, Volovics A, Hermus
RJ, Sturmans F. A large-scale prospective cohort study on diet and
cancer in The Netherlands. J Clin Epidemiol. 1990;43:285–95.
31. Van den Brandt PA, Schouten LJ, Goldbohm RA, Dorant E, Hunen PM.
Development of a record linkage protocol for use in the Dutch Cancer
Registry for Epidemiological Research. Int J Epidemiol. 1990;19:553–8.
32. Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH,
Pachen MM, Smits KM, de Bruine AP, Goldbohm RA, et al. K-ras
oncogene mutations in sporadic colorectal cancer in The Netherlands
Cohort Study. Carcinogenesis. 2003;24:703–10.
33. Nevo table. Dutch food composition table 1986–1987. 1986.
34. Goldbohm RA, van den Brandt PA, Brants HA, van’t Veer P, Al M,
Sturmans F, Hermus RJ. Validation of a dietary questionnaire used in a
large-scale prospective cohort study on diet and cancer. Eur J Clin Nutr.
1994;48:253–65.
35. Konings EJ. A validated liquid chromatographic method for determin-
ing folates in vegetables, milk powder, liver, and flour. J AOAC Int.
1999;82:119–27.
36. Konings EJ, Roomans HH, Dorant E, Goldbohm RA, Saris WH, van
den Brandt PA. Folate intake of the Dutch population according to
newly established liquid chromatography data for foods. Am J Clin
Nutr. 2001;73:765–76.
37. Lin DY, Wei LJ. The robust inference for the Cox Proportional Hazards
Model. JASA. 1989;84:1074–8.
38. Schoenfeld D. Partial residuals for the proportional hazards regression
models. Biometrika. 1982;69:239–41.
39. Diergaarde B, Vrieling A, van Kraats AA, van Muijen GN, Kok FJ,
Kampman E. Cigarette smoking and genetic alterations in sporadic
colon carcinomas. Carcinogenesis. 2003;24:565–71.
40. Larsson SC, Giovannucci E, Wolk A. A prospective study of dietary
folate intake and risk of colorectal cancer: modification by caffeine
intake and cigarette smoking. Cancer Epidemiol Biomarkers Prev.
2005;14:740–3.
41. Halsted CH, Villanueva JA, Devlin AM, Chandler CJ. Metabolic
interactions of alcohol and folate. J Nutr. 2002;132:2367S–72S.
42. Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC,
Colditz GA. Comparison of risk factors for colon and rectal cancer. Int J
Cancer. 2004;108:433–42.
43. van den Donk M, Buijsse B, van den Berg SW, Ocke MC, Harryvan JL,
Nagengast FM, Kok FJ, Kampman E. Dietary intake of folate and
riboflavin, MTHFR C677T genotype, and colorectal adenoma risk: a
Dutch case-control study. Cancer Epidemiol Biomarkers Prev. 2005;
14:1562–6.
44. Larsson SC, Giovannucci E, Wolk A. Vitamin b6 intake, alcohol
consumption, and colorectal cancer: a longitudinal population-based
cohort of women. Gastroenterology. 2005;128:1830–7.
45. ChanAT,MaJ,TranahGJ,GiovannucciEL,RifaiN,HunterDJ,FuchsCS.
Hemochromatosis gene mutations, body iron stores, dietary iron, and
risk of colorectal adenoma in women. J Natl Cancer Inst. 2005;97:
917–26.
46. Kim YI. Will mandatory folic acid fortification prevent or promote
cancer? Am J Clin Nutr. 2004;80:1123–8.
47. Fodde R. The APC gene in colorectal cancer. Eur J Cancer. 2002;
38:867–71.
48. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J,
Garner RC, Steele RJ, Wolf CR. Mutations in APC, Kirsten-ras, and
p53–alternative genetic pathways to colorectal cancer. Proc Natl Acad
Sci USA. 2002;99:9433–8.
49. Chiang JM, Wu Chou YH, Ma SC, Chen JR. Influence of age on
adenomatous polyposis coli and p53 mutation frequency in sporadic
colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras,
and p53 genes. Virchows Arch. 2004;445:465–71.
50. van Engeland M, Weijenberg MP, Roemen GM, Brink M, de Bruine AP,
Goldbohm RA, van den Brandt PA, Baylin SB, de Goeij AF, et al. Effects
of dietary folate and alcohol intake on promoter methylation in
sporadic colorectal cancer: the Netherlands cohort study on diet and
cancer. Cancer Res. 2003;63:3133–7.
51. Halford S, Rowan A, Sawyer E, Talbot I, Tomlinson IO. (6)-
methylguanine methyltransferase in colorectal cancers: detection of
mutations, loss of expression, and weak association with G:C.A:T
transitions. Gut. 2005;54:797–802.
Folate and APC mutations in colorectal cancer 3021
 at Universiteit M
aastricht UB Randwijck - Verwerking on December 19, 2008 
jn.nutrition.org
D
ow
nloaded from
 
